Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-849-6 | CAS number: 873-69-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05 - 27 March 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Pyridine-2-carbaldehyde oxime
- EC Number:
- 212-849-6
- EC Name:
- Pyridine-2-carbaldehyde oxime
- Cas Number:
- 873-69-8
- Molecular formula:
- C6H6N2O
- IUPAC Name:
- pyridine-2-carbaldehyde oxime
- Test material form:
- other: crystals
- Details on test material:
- - Name of test material (as cited in study report): Pyridin-2-aldoxim
- Physical state : white crystals
- Analytical purity : at least 98%
- Lot/batch No. : 7054 046 172
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: rats outbred with Wistarstock KFM:WIST (SPF HAN.)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Kleintierfarm Madoerin AG/ 4414 Fuellingsdorf, Switzerland
- Age at study initiation: 9-12 weeks
- Weight at study initiation: 203 - 269 g (males) and 174 - 214 g (females)
- Fasting period before study: 12 - 18 hours
- Housing: the animals were caged in groups of five in macrolon cages with standard softwood bedding ("Lignocel", Schill AG, 4132 Muttenz, Switzerland). The cages were cleaned twice weekly during the test period.
- Diet (e.g. ad libitum): pelleted standard KLIBA 343/BATCH 36/85 rat maintenance diet (Klingentalmuehle AG/ 4303 Kaiseraugust/Switzerland), available ad libitum. Results of analysis for contaminants are included in the original report.
- Water (e.g. ad libitum): tap water available ad libitum. Results of analyses for contaminants are incIuded in the original report.
- Acclimation period: at least one week under laboratory conditions, after veterinary examination.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3°C
- Humidity (%): 40-70%
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12 hours light, 12 hours dark
IDENTIFICATION: by unique cage number and corresponding color-coded spots.
RANDOMIZATION: randomly selected at time of delivery in groups of five.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 4 % solution of CMC (Carboxymethylcellulose sodium salt purum/ Fluka AG/ CH-9470 Buchs/Switzerland) in distilled water
- Amount of vehicle (if gavage): 10 mL at 100 mg/kg, 250 mg/kg, 600 mg/kg, 1000 mg/kg and 20 mL at 5000 mg/kg
MAXIMUM DOSE VOLUME APPLIED: 20 mL at 5000 mg/kg
DOSAGE PREPARATION: A weight by volume dilution of the test compound was prepared using a homogenizer (Ultra-Turrax/Janke and Kunkel/Staufen/ West-Germany) and kept homogenous during treatment using a magnetic stirrer (Auer-Bittmann/Switzerland). The preparation was made immediately prior to dosing. - Doses:
- 100 mg/kg bw, 250 mg/kg bw, 600 mg/kg bw, 1000 mg/kg bw and 5000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- not specified
- Details on study design:
- - single oral intubation via gavage to animals fasted for 12 to 18 hours
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Bodyweights were recorded at the test days 1 (pre-administration), 8 and 15. / Symptoms were assessed four times at day 1 and then daily
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight - Statistics:
- The LOGIT-Model (COX, Analysis of Binary Data, London 1977) was applied to estimate the toxicity value. Additionally, the 90, 95 and 99 % confidence intervals for the toxicity for each sex the slope of the dose response line were estimated.
Results and discussion
Effect levelsopen allclose all
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 388 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 261 - <= 577
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 350 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 201 - <= 609
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 383 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 180 - <= 815
- Mortality:
- For detailed results see Table 1 at "any other information on results incl. tables"
- Clinical signs:
- 100 mg/kg : sedation, dyspnea, ataxia, curved body position, ruffled fur.
250 mg/kg : sedation, dyspnea, ataxia, curved body position, ruffled fur.
600 mg/kg : sedation, dyspnea, ataxia, ventral body position, latero-abdominal position, curved body position, ruffled fur.
1000 mg/kg : sedation, dyspnea, ataxia, ventral body position, latero-abdominal position, curved body position, ruffled fur.
5000 mg/kg : sedation, dyspnea, ataxia, ventral body position, latero-abdominal position, curved body position. - Body weight:
- Males
mean body weight in g at day 1 / 8 / 15 :
Dose 100 mg/kg : 210 ±5.5 / 243 ±12 / 272 ±18
Dose 250 mg/kg : 205 ±2.1 / 232 ±11 / 258 ±12
Dose 600 mg/kg : 220 ±8.8 / DEAD / ---
Dose 1000 mg/kg : 254 ±11 /DEAD / ---
Dose 5000 mg/kg : 225 ±11 / DEAD / ---
Females :
mean body weight in g at day 1 / 8 / 15 :
Dose 100 mg/kg : 188 ±5.2 / 198 ±5.7 / 208 ±6.5
Dose 250 mg/kg : 185 ±7.3 / 189 / 196
Dose 600 mg/kg : 191 ±4.4 / DEAD / ---
Dose 1000 mg/kg : 199 ±9.6 /203 / 216
Dose 5000 mg/kg : 196 ±8.3 / DEAD / --- - Gross pathology:
- 100 mg/kg:
-Killed - Lung: mottled, dark-red (1); mottled, slight (2); No pathologic changes (7).
250 mg/kg:
-Dead
Lung: mottled, slight (1)
Stomach: filled, severe (1)
Intestines: partly reddened, with reddish contents (1)
Urinary bladder: filled with reddish contents (1)
-Killed
Lung: dark-red mottled (3.); mottled slight (2); No pathologic changes (4)
600 mg/kg:
-Dead
Lung: mottled (7), slight (2), dark-red (4)
Liver: dark-red mottled (1)
Stomach/Intestines: reddened, with reddish contents (2); reddened, mottled, dark-red, partial severe (3); with reddish partial severe dark-red contents (2); with orange to red, partial severe dark-red contents (1); reddened, severe, with dark-red contents (1)
Stomach: slightly reddened, with reddish contents (3) reddened, with red contents (1)
Intestines: severe reddened, with dark-red contents (3); reddened, with dark-red contents (1)
Urinary bladder: filled with reddish contents (5); reddened, with reddish contents (1)
1000 mg/kg:
-Dead
Lung: dark-red (1), dark-red mottled (6)
Liver: mottled, dark-red (4)
Stomach/Intestines: reddened (2), slight (1), red contents (1)
Stomach: reddened (2), slight (3), with reddish contents (6), filled (1)
Intestines: reddened severe (3), dark-red, severe (2), contents, red (1), dark-red (3), severe (2)
Urinary bladder: reddened, slight (2), filled with reddish contents (1), filled with dark-red contents (2); filled, severe, with reddish contents (1).
-Killed
No pathologic changes (1)
5000 mg/kg:
-Dead
Stomach/Intestines: reddened, slight (10). - Other findings:
- No other findings were reported.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Remarks:
- EU implementation
- Conclusions:
- LD50 : 388 mg/kg (male/females)
LD50 : 350 mg/kg (male)
LD50 : 383 mg/kg (females)
The study was performed according to the OECD TG401 without deviations and therefore considered to be of the highest quality (reliability Klimisch 1). The validity criteria of the test system are fulfilled. - Executive summary:
The acute oral toxicity of the test material was investigated in rats according to OECD TG401. The test substance Pyridin-2 -aldoxim was administered to rats of both sexes by oral gavage, at doses from 100 to 5000 mg/kg. The following death rate was observed :
0 % at 100 mg/kg *
10 % at 250 mg/kg *
100 % at 600 mg/kg *
90 % at 1000 mg/kg *
100 % at 5000 mg/kg
* Selected for the LOGIT-Estimation
Based on these observations, the LOGIT-ESTIMATION for the acute oral toxicity of Pyridin-2 -aldoxim in rats observed for a period of 15 days is:
LD50 : 388 mg/kg (male/females)
LD50 : 350 mg/kg (male)
LD50 : 383 mg/kg (females)
with a 95% confidence interval of :
Males/Females : 261 - 577 mg/kg
Males : 201 - 609 mg/kg
Females : 180 - 815 mg/kg
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.